Bicycle Therapeutics plc

NASDAQ:BCYC

Biotechnology

Healthcare
$3.20 -1.36%

-$0.06 today

Market cap
$224.30M
Beta
1.54
P/E (TTM)
-1.3
EPS (TTM)
-$3.14
52W Low $3.95High $9.18

Volume 0.45M

Average 0.49M

BCYC EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Bicycle Therapeutics plcNASDAQ: BCYC

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$59.48M, compared with -$60.25M a year earlier. Trailing-twelve-month EBITDA was -$211.5M.

Context

  • EBITDA amounted to 292.3% of revenue in FY2025, down 175.1 pp from a year earlier.
  • EBITDA grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 7 analysts of -$148.78M (+29.9%) for the fiscal year ending Dec 2026, a step up from the -28.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$59.48M-239.9% QoQ
Last fiscal yearDec 2025
-$212.18M-28.7% YoY
LTMMar 2026
-$211.5M-0.8% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.3%+49.4%+48.1 pp
1 year-28.7%+29.9%+58.6 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(212.18M) USD
Year-over-year change
-28.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How BCYC compares with its peers on the latest reported figures

  • BCYC's LTM Mar 2026 EBITDA of -$211.5M is the 9th highest of the 10 companies compared; the peer median is -$74.74M.
  • Its year-over-year change of -0.8% is the 7th highest of 9, against a peer median of +14.5%.
  • EBITDA amounts to 333.1% of revenue for BCYC, versus a peer median of 117.0%.
BCYC Competitors Peer median
EBITDA for BCYC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OMEROmeros CorporationLTM Mar 2026$92.9M +159.9%—939.0%
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026-$17.44M +88.7%—25.0%
CMPXCompass Therapeutics, Inc.LTM Mar 2026-$67.05M -25.2%——
PRTAProthena Corporation plcLTM Mar 2026-$74.72M +35.0%—129.0%
FULCFulcrum Therapeutics, Inc.LTM Mar 2026-$74.74M -18129.5%——
ADCTADC Therapeutics S.A.LTM Mar 2026-$83.2M +13.7%—105.1%
KALVKalVista Pharmaceuticals, Inc.LTM Dec 2025-$117.15M ——101.1%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026-$163.43M +3.9%—185.2%
BCYCBicycle Therapeutics plcLTM Mar 2026-$211.5M -0.8%—333.1%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026-$217.64M +15.4%——
Peer median (excluding BCYC) -$74.74M+14.5%—117.0%

Competitors are the stored peer set for BCYC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue11.7M14.46M26.98M35.28M72.59M
Cost of Revenue00156.5M172.97M0
Gross Profit11.7M14.46M(129.52M)(137.69M)72.59M
Gross Margin100.0%100.0%-480.1%-390.3%100.0%
Research & Development44.88M81.61M156.5M172.97M240.28M
Selling, General & Admin32.44M49.51M59.83M71.46M80.02M
Operating Expenses77.32M131.12M60.43M72.18M320.3M
Depreciation & Amortization1.41M3.69M6.55M7.18M6.42M
EBITDA(64.09M)(107.21M)(169.4M)(164.89M)(212.18M)
EBITDA Margin-547.9%-741.3%-628.0%-467.4%-292.3%
Operating Income(65.62M)(116.65M)(189.95M)(209.87M)(247.72M)
Operating Margin-561.0%-806.6%-704.1%-595.0%-341.3%
Interest Income120K5.76M14M34.28M28.46M
Interest Expense2.98M3.34M3.26M1.73M206K
Other Income / Expenses(2.86M)2.41M10.74M36.08M28.91M
Income Before Tax(68.48M)(114.24M)(179.21M)(173.8M)(218.81M)
Pre-Tax Margin-585.5%-789.9%-664.3%-492.7%-301.4%
Income Tax Expense(1.66M)(1.52M)1.46M(4.77M)152K
Net Income(66.82M)(112.72M)(180.66M)(169.03M)(218.96M)
Net Margin-571.2%-779.3%-669.7%-479.2%-301.7%
EPS (Basic)(2.67)(3.80)(5.08)(2.91)(3.16)
EPS (Diluted)(2.67)(3.80)(5.08)(2.90)(3.16)
Weighted Avg Shares25.06M29.66M35.59M58.21M69.28M
Weighted Avg Shares (Diluted)25.06M29.66M35.59M58.21M69.28M

Bicycle Therapeutics plc

NASDAQ:BCYC

Intrinsic Alpha fair value

Locked

Current Price

$3.20

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.